Question explored with the scientific record
Conversation so far
- 1 What does long term pregabalin use do to you?
- 2 What withdrawal symptoms and timeline are reported after stopping?
- 3 Are there safer alternatives to pregabalin that lower withdrawal risk?
- 4 What taper schedule has the best evidence to reduce pregabalin withdrawal?
Answered on this page ↓
What taper schedule has the best evidence to reduce pregabalin withdrawal?
The short version: no taper schedule for pregabalin has been tested in any study in this retrieval.
The evidence you have is a collection of studies about pregabalin for other conditions. None of them tested how to stop the drug. The fibromyalgia trials [4, 6, 9] and the alcohol-dependence studies [1, 7] report what happens when patients take pregabalin, not what happens when they stop. The benzodiazepine-withdrawal study [2] used pregabalin as the treatment, not as the drug being withdrawn. A case report [3] describes a rare adverse event during treatment, not a taper schedule.
The most informative design for your question would be a randomized trial comparing different taper speeds, dose reductions, or durations, with withdrawal symptoms as the measured outcome. That study does not appear in this retrieval. The manufacturer-funded trials report dizziness and somnolence as side effects during treatment [4] but do not report what happens when the drug is discontinued. The question you are asking was never studied in the evidence here.
My call: there is no evidence in this retrieval to support any specific pregabalin taper schedule. Confidence: low, because the question was not tested.
Sources examined 10
-
Pregabalin in the Treatment of Alcohol and Benzodiazepines Dependence
This review evaluates the efficacy and safety of pregabalin in treating alcohol and benzodiazepine dependence, highlighting its potential as a novel therapeutic option despite the limitations of the studies reviewed.
DOI: 10.1111/j.1755-5949.2009.00120.x -
PW01-241 - The Effect Of Pregabalin On Subjective Sleep Problems During Withdrawal From Long-Term Benzodiazepine Use
This study evaluates whether pregabalin used during tapering aids subjective sleep quality in adults withdrawing from long-term benzodiazepine use, reporting substantial MOS-Sleep improvements and correlations with anxiety and illness severity in a 12-week observational analysis.
DOI: 10.1016/s0924-9338(10)71648-5 -
A Case Report on Pregabalin-Induced Eosinophilia
A rare case of pregabalin-induced eosinophilia in a 77-year-old man with diabetes, which resolved after stopping pregabalin and starting steroid therapy, with causality deemed probable by ADR assessment scales.
DOI: 10.4140/tcp.n.2018.317 -
A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
This randomized, double-blind, multicenter phase III trial in Japan shows that pregabalin up to 450 mg/day significantly reduces pain and improves sleep and functioning in Japanese patients with fibromyalgia, with a manageable safety profile.
DOI: 10.1186/ar4056 -
Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia
This study evaluates the efficacy and safety of once-daily controlled-release pregabalin in patients with postherpetic neuralgia, demonstrating significant improvements in pain management compared to placebo.
DOI: 10.1097/AJP.0000000000000445 -
Pregabalin and Fibromyalgia Syndrome: A Treatment Option
A comprehensive review of pregabalin as a treatment for fibromyalgia, detailing its pharmacology and pharmacokinetics and summarizing four randomized trials (8-, 13-, and 14-week monotherapy plus the FREEDOM trial) that show pregabalin can reduce pain and improve sleep and quali…
DOI: 10.4137/CMT.S1094 -
P.6.b.001 A double-blind placebo-controlled randomised trial of pregabalin for alcohol dependence: interim analysis
This study investigates the effects of early life stress and ethanol binge-like drinking on gene expression and DNA methylation in the hypothalamus and pituitary of rats, revealing significant long-term changes in Pomc expression and its correlation with anxiety-like behavior du…
DOI: 10.1016/s0924-977x(14)71068-5 -
Investigating psychotropic properties of antiepileptic drugs
This expert review surveys how antiepileptic drugs exert psychotropic effects across epilepsy and psychiatric disorders by targeting GABAergic, glutamatergic, and other neuronal pathways, highlighting promising agents (e.g., lamotrigine, pregabalin, valpromide/valnoctamide, gana…
DOI: 10.1586/ern.13.57 -
Fibromyalgia syndrome: epidemiology, diagnosis and treatment
Fibromyalgia syndrome is a common chronic pain disorder with evolving diagnostic criteria and multimodal management integrating drugs like pregabalin and duloxetine with exercise, CBT, and education.
DOI: 10.5114/reum.2022.123671 -
A Severe Case of Recalcitrant Pompholyx
A case report describing a 34-year-old woman with severe recalcitrant pompholyx who failed multiple systemic treatments and showed marked improvement with radiotherapy.
DOI: 10.1177/1203475415581737